LGALS9 and myelodysplastic syndrome: The median percentage of Gal‐9 in MDSCs from MDS patients (n = 29, samples: 001‐031, except 005 and 018) was significantly higher than that in NC (17.21% (8.74%‐35.77%) vs 2.61% (1.19%‐3.39%), P < .0001****), but there was no difference between the low‐risk and high‐risk groups (16.86% (7.15%‐39.19%) vs 20.72% (10.74%‐36.35%), P = .7148) (Figure 1A‐C).